Last reviewed · How we verify

Balversa — Competitive Intelligence Brief

Balversa (ERDAFITINIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Fibroblast growth factor receptor 1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Balversa (ERDAFITINIB) — Johnson & Johnson. Balversa works by blocking the fibroblast growth factor receptor 1, a protein that helps cancer cells grow and spread.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Balversa TARGET ERDAFITINIB Johnson & Johnson marketed Kinase Inhibitor [EPC] Fibroblast growth factor receptor 1 2019-01-01
Pemazyre PEMIGATINIB Incyte Corp marketed Kinase Inhibitor [EPC] Fibroblast growth factor receptor 1 2020-01-01
ABT-712 ABT-712 AbbVie (prior sponsor, Abbott) phase 3 FGFR1 inhibitor FGFR1 (Fibroblast Growth Factor Receptor 1)
AZD0120 AZD0120 AstraZeneca phase 3 FGFR1 inhibitor FGFR1 (Fibroblast Growth Factor Receptor 1)
Hernexeos ZONGERTINIB Boehringer Ingelheim marketed Kinase Inhibitor [EPC] 2025-01-01
Romvimza VIMSELTINIB Deciphera Pharms marketed Kinase Inhibitor [EPC] 2025-01-01
Itovebi INAVOLISIB Genentech Inc marketed Kinase Inhibitor [EPC] 2025-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor [EPC] class)

  1. · 12 drugs in this class
  2. Pfizer · 7 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Bayer · 2 drugs in this class
  5. Boehringer Ingelheim · 2 drugs in this class
  6. AstraZeneca · 2 drugs in this class
  7. Beigene Usa Inc · 1 drug in this class
  8. BeiGene · 1 drug in this class
  9. AbbVie · 1 drug in this class
  10. Bristol · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Balversa — Competitive Intelligence Brief. https://druglandscape.com/ci/erdafitinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: